Gemcitabine, dexamethasone and cisplatin (GDP) is an effective and well-tolerated mobilization regimen for relapsed and refractory lymphoma: a single center experience

Background/aim: Gemcitabine, dexamethasone and cisplatin (GDP) is a well-established salvage regimen for relapsed and refractory lymphomas. In this study, we aimed to share our experience with the patients who received GDP/R-GDP (rituximab-gemcitabine, dexamethasone and cisplatin) for stem cell mobilization. Materials and methods: Data of 69 relapsed and refractory Hodgkin lymphoma (HL) and Non-Hodgkin lymphoma (NHL) patients who received GDP/R-GDP as salvage chemotherapy in our center between July 2014 and January 2020 were retrospectively evaluated. After the evaluation of response, 52 patients had a chemosensitive disease and underwent mobilization with GDP/R-GDP plus G–CSF (granulocyte colony-stimulating factor). Collected CD34+ stem cells and related parameters were compared in terms of diagnosis of HL and NHL, early and late stage, patients who did not receive RT and those who received RT, and patients aged under 60 and over 60. Results: On the 15th day on average (range 11–20), a median number of 8.7 × 106 /kg (4.1–41.5) CD34+ stem cells were collected in 51 (98%) of our 52 chemosensitive patients and 1 (2%) patients failed to mobilize. We observed acceptable hematological and nonhematological toxicity. The targeted amount of 2 × 106 /kg CD34+ stem cells was attained by 98% (n: 51) patients, and all of them underwent autologous stem cell transplantation. Moreover, low toxicity profiles provide outpatient utilization option clinics with close follow-up and adequate supportive care. Conclusion: We suggest that GDP/R-GDP plus G-CSF can be used as an effective chemotherapy regimen for mobilizing CD34+ stem cells from peripheral blood in relapsed and refractory lymphoma patients due to low toxicity, effective tumor reduction, and successful stem cell mobilization. It can also be assumed that the GDP mobilization regimen may be more effective, especially in patients with early-stage disease and in HL patients.Key words: Gemcitabine, dexamethasone, cisplatin, stem cell mobilization, relapsed and refractory lymphoma

PDF

___

1. Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM et al. Aggressive conventional chemotherapy compared with highdose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial. The Lancet 2002; 359 (9323): 2065-2071. doi: 10.1016/S0140-6736(02)08938-9
2. Ozkan HA, Bal C, Gulbas Z. Chemomobilization with high-dose etoposide and G-CSF results in effective and safe stem cell collection in heavily pretreated lymphoma patients: report from a single institution study and review. European Journal of Haematology 2014; 92 (5): 390-397.
3. Beyer J, Schwella N, Zingsem J, Strohscheer I, Schwaner I et al. Hematopoietic rescue after high-dose chemotherapy using autologous peripheral-blood progenitor cells or bone marrow: a randomized comparison. Journal of Clinical Oncology 1995; 13 (6): 1328-1335. doi: 10.1200/JCO.1995.13.6.1328
4. Richman CM, Weiner RS, Yankee RA. Increase in circulating stem cells following chemotherapy in man. Blood 1976; 47: 1031- 1039.
5. Weaver CH, Schwartzberg LS, Birch R, Greco FA, Rhinehart S et al. Collection of peripheral blood progenitor cells after the administration of cyclophosphamide, etoposide, and granulocytecolony-stimulating factor: an analysis of 497 patients. Transfusion 1997; 37 (9): 896-903. doi: 10.1046/j.1537-2995.1997.37997454014.x
6. Mohty M, Hübel K, Kröger N, Aljurf M, Apperley J et al. Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation. Bone Marrow Transplantation 2014; 49 (7): 865-872. doi: 10.1038/bmt.2014.39
7. Stiff PJ, Micallef I, Nademanee AP, Stadtmauer EA, Maziarz RT et al. Transplanted CD34(+) cell dose is associated with longterm platelet count recovery following autologous peripheral blood stem cell transplant in patients with non-Hodgkin lymphoma or multiple myeloma. Biology of Blood and Marrow Transplantation 2011; 17 (8): 1146-1153. doi: 10.1016/j. bbmt.2010.11.021
8. Giralt S, Costa L, Schriber J, Dipersio J, Maziarz R et al. Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations. Biology of Blood and Marrow Transplantation 2014; 20 (3): 295-308. doi: 10.1016/j.bbmt.2013.10.013
9. Nakasone H, Kanda Y, Ueda T, Matsumoto K, Shimizu N et al. Retrospective comparison of mobilization methods for autologous stem cell transplantation in multiple myeloma. American Journal of Hematology 2009; 84 (12): 809-814. doi: 10.1002/ajh.21552
10. Pusic I, Jiang SY, Landua S, Uy GL, Rettig MP et al. Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation. Biology of Blood and Marrow Transplantation 2008; 14 (9): 1045-1056. doi: 10.1016/j.bbmt.2008.07.004
11. Hübel K. Mobilization and collection of HSC. In: Carreras E, Dufour C, Mohty M et al., editors. The EBMT handbook. Hematopoietic stem cell transplantation and cellular therapies. Cham, Switzerland: Springer Nature Switzerland AG; 2019. pp. 117-122.
12. To LB, Levesque JP, Herbert KE. How I treat patients who mobilize hematopoietic stem cells poorly. Blood 2011; 118 (17): 4530-4540.
13. Ford CD, Green W, Warenski S, Petersen FB. Effect of prior chemotherapy on hematopoietic stem cell mobilization. Bone Marrow Transplantation 2004; 33 (9): 901-905.
14. Van Heertum RL, Scarimbolo R, Wolodzko JG, Klencke B, Messmann R et al. Lugano 2014 criteria for assessing FDGPET/CT in lymphoma: an operational approach for clinical trials. Drug Design, Development and Therapy 2017; 13 (11): 1719-1728. doi: 10.2147/DDDT.S136988
15. Olivieri A, Marchetti M, Lemoli R, Tarella C, Iacone A et al. Proposed definition of ‘poor mobilizer’ in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo ItalianoTrapianto di Midollo Osseo. Bone Marrow Transplantation 2012; 47 (3): 342-351. doi: 10.1038/bmt.2011.82
16. Kuruvilla J, Nagy T, Pintilie M, Tsang R, Keating A et al. Similar response rates and superior early progression-free survival with gemcitabine, dexamethasone, and cisplatin salvage therapy compared with carmustine, etoposide, cytarabine, and melphalan salvage therapy prior to autologous stem cell transplantation for recurrent or refractory Hodgkin lymphoma. Cancer 2006; 106 (2): 353-360.
17. Moskowitz CH, Nimer SD, Zelenetz AD, Trippett T, Hedrick EE et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood 2001; 1; 97 (3): 616-623. doi: 10.1182/ blood.v97.3.616
18. Bozdağ SC, Tekgündüz E, Durgun G, Sarıca A, Demiriz IŞ et al. Which regimen is better for stem cell mobilization of lymphoma patients? Transfusion and Apheresis Science 2013; 48 (3): 407-410. doi: 10.1016/j.transci.2013.04.027.
19. Berber I, Erkurt MA, Kuku I, Kaya E, Bag HG et al. DHAP plus filgrastim as an effective peripheral stem cell mobilization regimen for autologous stem-cell transplantation in patients with relapsed/refractory lymphoma: a single center experience. Transfusion and Apheresis Science 2016; 54 (1): 48-52. doi: 10.1016/j.transci.2016.01.012
20. Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch DC et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. Journal of Clinical Oncology 2010; 20; 28 (27): 4184-4190. doi: 10.1200/ JCO.2010.28.1618
21. Moccia AA, Hitz F, Hoskins P, Klasa R, Power MM et al. Gemcitabine, dexamethasone, and cisplatin (GDP) is an effective and well-tolerated salvage therapy for relapsed/ refractory diffuse large B-cell lymphoma and Hodgkin lymphoma. Leukemia & Lymphoma 2017; 58 (2): 324-332. doi: 10.1080/10428194.2016.1193852
22. Abhyankar S, DeJarnette S, Aljitawi O, Ganguly S, Merkel D et al. A risk-based approach to optimize autologous hematopoietic stem cell (HSC) collection with the use of plerixafor. Bone Marrow Transplantation 2012; 47 (4): 483-487. doi: 10.1038/ bmt.2011.133
23. Kouroukis CT, Varela NP, Bredeson C, Kuruvilla J, Xenocostas A. Plerixafor for autologous stem-cell mobilization and transplantation for patients in Ontario. Current Oncology 2016; 23 (4): e409-e430. doi: 10.3747/co.23.3137
24. Tang C, Espin-Garcia O, Prica A, Kurkreti V, Kridel R et al. Efficacy and safety of stem cell mobilization following gemcitabine, dexamethasone, cisplatin (GDP) salvage chemotherapy in patients with relapsed or refractory lymphoma. Leukemia & Lymphoma 2020; 1: 1-8. doi: 10.1080/10428194.2020.1762882
25. Demiriz IŞ, Bozdağ SC, Tekgündüz E, Uğur B, Durgun G et al. Predicting the successful peripheral blood stem cell harvesting. Transfusion and Apheresis Science 2013; 48 (3): 411-414. doi: 10.1016/j.transci.2013.04.028
26. Dogu MH, Çagirgan S, Ocakci S, Kaya AH, Ilkkilic K et al. Autologous stem cell transplantation and stem cell mobilization kinetics in elderly patients with B cell non-Hodgkin lymphoma. Transfusion and Apheresis Science 2017; 56 (6): 814-818. doi: 10.1016/j.transci.2017.11.012